...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of dermatology >Enhanced CCR9 expression levels in psoriatic skin are associated with poor clinical outcome to infliximab treatment
【24h】

Enhanced CCR9 expression levels in psoriatic skin are associated with poor clinical outcome to infliximab treatment

机译：银屑病皮肤中CCR9表达水平升高与英夫利昔单抗治疗的临床效果差有关

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Infliximab is an anti-tumor necrosis factor (TNF)- antibody drug that suppresses TNF- and its associated inflammatory responses. Although infliximab therapy generally results in a 75% or greater improvement in the Psoriasis Area and Severity Index from baseline in psoriasis patients, there is the heterogeneity of therapeutic efficacy in psoriasis patients among patients of a similar PASI baseline score. However, there are few published reports about the predictors of the clinical response among psoriasis patients who undergo biologic therapies. We thus evaluated the possible existence of biologic markers that would indicate poor prognosis of infliximab using skin biopsy specimens. This was because we assumed that the inhibitors for upregulated chemokine/chemokine receptors in non-responders may have the ability to reduce the occurrence of psoriatic eruptions. PCR array analyses identified that the levels of various chemokines and chemokine receptors were increased in non-responders in comparison to responders. Immunohistochemical analyses revealed that upregulation of the CCR9 protein levels was not associated with the pretherapeutic PASI score, but with poor response to infliximab. Our results indicated that the expression levels of CCR9 in lesional skin may be a useful biologic marker of the clinical efficacy of infliximab therapy in psoriasis patients.
机译：英夫利昔单抗是一种抗肿瘤坏死因子（TNF）抗体药物，可抑制TNF-及其相关的炎症反应。尽管英夫利昔单抗治疗通常会使牛皮癣患者的银屑病面积和严重性指数较基线水平提高75％或更多，但在具有相似PASI基线评分的患者中，牛皮癣患者的治疗功效存在异质性。然而，很少有关于生物疗法治疗牛皮癣患者中临床反应预测因素的报道。因此，我们使用皮肤活检标本评估了可能指示英夫利昔单抗预后不良的生物标志物的存在。这是因为我们假设无反应者中趋化因子/趋化因子受体上调的抑制剂可能具有减少银屑病爆发的能力。 PCR阵列分析确定，与反应者相比，非反应者中各种趋化因子和趋化因子受体的水平增加。免疫组织化学分析显示，CCR9蛋白水平的上调与治疗前的PASI评分无关，但对英夫利昔单抗的反应较差。我们的结果表明，病变皮肤中CCR9的表达水平可能是英夫利昔单抗治疗牛皮癣患者临床疗效的有用生物学指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号